Skip to content

Study · Randomized controlled trial · n = 15 · 2022

6 results

Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjects.

Okabe K, Yaku K, Uchida Y, Fukamizu Y, Sato T, Sakurai T, Tobe K, Nakagawa T

Frontiers in nutrition11 Apr 2022Cited by 86 (Europe PMC)

PMID35479740 (opens in a new tab)PMCIDPMC9036060 (opens in a new tab)DOI10.3389/fnut.2022.868640 (opens in a new tab)PepBankPUB-35479740
Download PDFPubMedAsk about this study
Jump to 6 results

Summary

Nicotinamide mononucleotide (NNM) is an orally bioavailable NAD+ precursor that has demonstrated beneficial effects against aging and aging-associated diseases in animal models. NMN is ultimately converted to NAD+, a redox cofactor that mediates many metabolic enzymes. NAD+ also serves as the substrate for poly(ADP-ribose) polymerase (PARP) and sirtuins, and regulates various biological processes, such as metabolism, DNA repair, gene expression, and stress responses. Previous mouse models showed that NMN administration can increase NAD+ in various organs and ameliorate aging-related diseases, such as obesity, diabetes, heart failure, stroke, kidney failure, and Alzheimer's disease through NAD+-mediated pathways. However, evidence of its effect on humans is still scarce. In this study, we conducted a placebo-controlled, randomized, double blind, parallel-group trial to investigate the safety of orally administered NMN and its efficacy to increase NAD+ levels in thirty healthy subjects. Healthy volunteers received 250 mg/day of NMN (n = 15) or placebo (n = 15) for 12 weeks, and physiological and laboratory tests were performed during this period. In addition, NAD+ and its related metabolites in whole blood were examined. Oral supplementation of NMN for 12 weeks caused no abnormalities in physiological and laboratory tests, and no obvious adverse effects were observed. NAD+ levels in whole blood were significantly increased after NMN administration. We also observed the significant rise in nicotinic acid mononucleotide (NAMN) levels, but not in NMN. We also found that the increased amount of NAD+ was strongly correlated with pulse rate before the administration of NMN. These results suggest that oral administration of NMN is a safe and practical strategy to boost NAD+ levels in humans. Clinical Trial Registration: JRCT [https://jrct.niph.go.jp/], identifier: [jRCTs041200034].
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialSafety outcome

    In healthy adults, 12 weeks of NMN caused no abnormalities in physiological and laboratory tests.

    In plain wordsIn healthy adults, 12 weeks of NMN caused no abnormal results in physiological and laboratory tests.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    No significant changePhysiological and laboratory test abnormalities
    Study

    n = 15

    Outcome group
    Adverse events · Whole body
    Studied dose
    250 mg/day · oral · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Oral supplementation of NMN for 12 weeks caused no abnormalities in physiological and laboratory tests, and no obvious adverse effects were observed.
    2 context sentences
    Summary · context
    In this study, we conducted a placebo-controlled, randomized, double blind, parallel-group trial to investigate the safety of orally administered NMN and its efficacy to increase NAD+ levels in thirty healthy subjects.
    Summary · context
    Healthy volunteers received 250 mg/day of NMN (n = 15) or placebo (n = 15) for 12 weeks, and physiological and laboratory tests were performed during this period.
  2. 02HumanRandomized controlled trialSafety outcome

    In healthy adults, investigators observed no obvious adverse effects during NMN supplementation.

    In plain wordsIn healthy adults, investigators observed no obvious adverse effects during NMN supplementation.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    No significant changeObvious adverse effects
    Study

    n = 15

    Outcome group
    Adverse events · Whole body
    Studied dose
    250 mg/day · oral · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Oral supplementation of NMN for 12 weeks caused no abnormalities in physiological and laboratory tests, and no obvious adverse effects were observed.
    2 context sentences
    Summary · context
    In this study, we conducted a placebo-controlled, randomized, double blind, parallel-group trial to investigate the safety of orally administered NMN and its efficacy to increase NAD+ levels in thirty healthy subjects.
    Summary · context
    Healthy volunteers received 250 mg/day of NMN (n = 15) or placebo (n = 15) for 12 weeks, and physiological and laboratory tests were performed during this period.
  3. 03HumanRandomized controlled trialActivity measurement

    In healthy adults, whole-blood NAD+ increased significantly after NMN administration.

    In plain wordsIn healthy adults, whole-blood NAD+ increased after NMN administration.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreaseWhole-blood NAD+
    Study

    n = 15

    Outcome group
    Metabolic pathways and metabolomics · Whole body
    Studied dose
    250 mg/day · oral · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    NAD+ levels in whole blood were significantly increased after NMN administration.
    2 context sentences
    Summary · context
    In this study, we conducted a placebo-controlled, randomized, double blind, parallel-group trial to investigate the safety of orally administered NMN and its efficacy to increase NAD+ levels in thirty healthy subjects.
    Summary · context
    Healthy volunteers received 250 mg/day of NMN (n = 15) or placebo (n = 15) for 12 weeks, and physiological and laboratory tests were performed during this period.
  4. 04HumanRandomized controlled trialActivity measurement

    In healthy adults, whole-blood NAMN increased significantly during NMN supplementation.

    In plain wordsIn healthy adults, blood NAMN increased during NMN supplementation.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreaseWhole-blood NAMN
    Study

    n = 15

    Outcome group
    Metabolic pathways and metabolomics · Whole body
    Studied dose
    250 mg/day · oral · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    We also observed the significant rise in nicotinic acid mononucleotide (NAMN) levels, but not in NMN.
    3 context sentences
    Summary · context
    In addition, NAD+ and its related metabolites in whole blood were examined.
    Summary · context
    In this study, we conducted a placebo-controlled, randomized, double blind, parallel-group trial to investigate the safety of orally administered NMN and its efficacy to increase NAD+ levels in thirty healthy subjects.
    Summary · context
    Healthy volunteers received 250 mg/day of NMN (n = 15) or placebo (n = 15) for 12 weeks, and physiological and laboratory tests were performed during this period.
  5. 05HumanRandomized controlled trialPharmacokinetics

    In healthy adults, whole-blood NMN did not increase significantly during NMN supplementation.

    In plain wordsIn healthy adults, blood NMN did not increase significantly during NMN supplementation.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    No significant changeWhole-blood NMN
    Study

    n = 15

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    250 mg/day · oral · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    We also observed the significant rise in nicotinic acid mononucleotide (NAMN) levels, but not in NMN.
    3 context sentences
    Summary · context
    In addition, NAD+ and its related metabolites in whole blood were examined.
    Summary · context
    In this study, we conducted a placebo-controlled, randomized, double blind, parallel-group trial to investigate the safety of orally administered NMN and its efficacy to increase NAD+ levels in thirty healthy subjects.
    Summary · context
    Healthy volunteers received 250 mg/day of NMN (n = 15) or placebo (n = 15) for 12 weeks, and physiological and laboratory tests were performed during this period.
  6. 06HumanRandomized controlled trialOther

    In healthy adults, the NAD+ increase after NMN correlated strongly with baseline pulse rate.

    In plain wordsIn healthy adults, the NAD+ increase after NMN was linked to baseline pulse rate.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    Direction not reportedNAD+ increase correlation with baseline pulse rate
    Study

    n = 15

    Outcome group
    Metabolic pathways and metabolomics · Whole body
    Studied dose
    250 mg/day · oral · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    We also found that the increased amount of NAD+ was strongly correlated with pulse rate before the administration of NMN.
    2 context sentences
    Summary · context
    In this study, we conducted a placebo-controlled, randomized, double blind, parallel-group trial to investigate the safety of orally administered NMN and its efficacy to increase NAD+ levels in thirty healthy subjects.
    Summary · context
    Healthy volunteers received 250 mg/day of NMN (n = 15) or placebo (n = 15) for 12 weeks, and physiological and laboratory tests were performed during this period.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 ongoing · source ClinicalTrials.gov (opens in a new tab)

RecruitingPhase 2NCT06991712

Comparisons of NAD Precursors for Neuroenhancement in Glaucoma Patients

Christopher Kai Shun Leungn = 13819 May 2025 to est. 31 Dec 2026

Glaucoma

Trial pageClinicalTrials.govUpdated 26 Jun 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.